Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...
SAN DIEGO—Cytiva has launched its Sefia next-generation manufacturing platform, with the goal of helping drug developers and larger healthcare providers accelerate their production of chimeric antigen ...
Data integrity is key to the success of any cell therapy program. CDMOs can implement robust data management systems for ...
When most people think of cancer care, they rarely associate it with what goes on behind the scenes to create life-saving treatments. For starters, developing cell and gene therapies is pricey, and ...
Whether for drug screening or toxicity testing, stem cell-based 3D tissue models are key to biomedical research. However, ...
Cellares. Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to ...
Cellares has joined forces with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford Innovative ...
The global photovoltaic (PV) industry is entering a phase defined less by headline capacity additions and more by incremental but compounding improvements in efficiency, reliability, and ...
DUBLIN--(BUSINESS WIRE)--The "Point-of-Care Cell and Gene Therapy Manufacturing Market - A Global and Regional Analysis: Focus on Technology, Therapeutic Area, End User, and Regional Analysis - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results